| Browse |
| Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants. |
| Lineage (WHO label)   | Target Gene | Primer Name | Primer Sequence | Primer Length | Primer GC Content (%) | Start Position | End Position | Primer Direction | ΔG (cal) | Primer first used |
|---|---|---|---|---|---|---|---|---|---|---|
| JN.3.2 | N | US-CDC-N-2 | GCGCGACATTCCGAAGAA | 18 | 55.56 | 29230 | 29213 | R | -21404.2 | US |
| GE.1.2.2 | N | US-CDC-N-2 | TTACAAACATTGGCCGCAAA | 20 | 40 | 29164 | 29183 | F | -21115.5 | US |
| GE.1.2.2 | N | US-CDC-N-2 | GCGCGACATTCCGAAGAA | 18 | 55.56 | 29230 | 29213 | R | -21404.2 | US |
| JN.1.58.1 | N | US-CDC-N-2 | TTACAAACATTGGCCGCAAA | 20 | 40 | 29164 | 29183 | F | -21115.5 | US |
| JN.1.58.1 | N | US-CDC-N-2 | GCGCGACATTCCGAAGAA | 18 | 55.56 | 29230 | 29213 | R | -21404.2 | US |
| MN.1 | N | US-CDC-N-2 | TTACAAACATTGGCCGCAAA | 20 | 40 | 29164 | 29183 | F | -21115.5 | US |
| MN.1 | N | US-CDC-N-2 | GCGCGACATTCCGAAGAA | 18 | 55.56 | 29230 | 29213 | R | -21404.2 | US |
| JN.1.63 | N | US-CDC-N-2 | TTACAAACATTGGCCGCAAA | 20 | 40 | 29164 | 29183 | F | -21115.5 | US |
| JN.1.63 | N | US-CDC-N-2 | GCGCGACATTCCGAAGAA | 18 | 55.56 | 29230 | 29213 | R | -21404.2 | US |
| LE.1.3 | N | US-CDC-N-2 | TTACAAACATTGGCCGCAAA | 20 | 40 | 29164 | 29183 | F | -21115.5 | US |
| LE.1.3 | N | US-CDC-N-2 | GCGCGACATTCCGAAGAA | 18 | 55.56 | 29230 | 29213 | R | -21404.2 | US |
| LH.2 | N | US-CDC-N-2 | TTACAAACATTGGCCGCAAA | 20 | 40 | 29164 | 29183 | F | -21115.5 | US |
| LH.2 | N | US-CDC-N-2 | GCGCGACATTCCGAAGAA | 18 | 55.56 | 29230 | 29213 | R | -21404.2 | US |
| HW.1.1 | N | US-CDC-N-2 | TTACAAACATTGGCCGCAAA | 20 | 40 | 29164 | 29183 | F | -21115.5 | US |
| HW.1.1 | N | US-CDC-N-2 | GCGCGACATTCCGAAGAA | 18 | 55.56 | 29230 | 29213 | R | -21404.2 | US |
| JN.1.55.2 | N | US-CDC-N-2 | TTACAAACATTGGCCGCAAA | 20 | 40 | 29164 | 29183 | F | -21115.5 | US |
| JN.1.55.2 | N | US-CDC-N-2 | GCGCGACATTCCGAAGAA | 18 | 55.56 | 29230 | 29213 | R | -21404.2 | US |
| JN.1.18.1 | N | US-CDC-N-2 | TTACAAACATTGGCCGCAAA | 20 | 40 | 29164 | 29183 | F | -21115.5 | US |
| JN.1.18.1 | N | US-CDC-N-2 | GCGCGACATTCCGAAGAA | 18 | 55.56 | 29230 | 29213 | R | -21404.2 | US |
| XDK.4.1 | N | US-CDC-N-2 | TTACAAACATTGGCCGCAAA | 20 | 40 | 29164 | 29183 | F | -21115.5 | US |
| XDK.4.1 | N | US-CDC-N-2 | GCGCGACATTCCGAAGAA | 18 | 55.56 | 29230 | 29213 | R | -21404.2 | US |
| KP.3.4.1 | N | US-CDC-N-2 | TTACAAACATTGGCCGCAAA | 20 | 40 | 29164 | 29183 | F | -21115.5 | US |
| KP.3.4.1 | N | US-CDC-N-2 | GCGCGACATTCCGAAGAA | 18 | 55.56 | 29230 | 29213 | R | -21404.2 | US |
| KP.2.11 | N | US-CDC-N-2 | TTACAAACATTGGCCGCAAA | 20 | 40 | 29164 | 29183 | F | -21115.5 | US |
| KP.2.11 | N | US-CDC-N-2 | GCGCGACATTCCGAAGAA | 18 | 55.56 | 29230 | 29213 | R | -21404.2 | US |
| LS.1 | N | US-CDC-N-2 | TTACAAACATTGGCCGCAAA | 20 | 40 | 29164 | 29183 | F | -21115.5 | US |
| LS.1 | N | US-CDC-N-2 | GCGCGACATTCCGAAGAA | 18 | 55.56 | 29230 | 29213 | R | -21404.2 | US |
| BA.1.1 (Omicron) | N | US-CDC-N-2 | TTACAAACATTGGCCGCAAA | 20 | 40 | 29164 | 29183 | F | -21115.5 | US |
| BA.1.1 (Omicron) | N | US-CDC-N-2 | GCGCGACATTCCGAAGAA | 18 | 55.56 | 29230 | 29213 | R | -21404.2 | US |
| BA.5.2.14 | N | US-CDC-N-2 | TTACAAACATTGGCCGCAAA | 20 | 40 | 29164 | 29183 | F | -21115.5 | US |
| BA.5.2.14 | N | US-CDC-N-2 | GCGCGACATTCCGAAGAA | 18 | 55.56 | 29230 | 29213 | R | -21404.2 | US |
| BA.4 (Omicron) | N | US-CDC-N-2 | TTACAAACATTGGCCGCAAA | 20 | 40 | 29164 | 29183 | F | -21115.5 | US |
| BA.4 (Omicron) | N | US-CDC-N-2 | GCGCGACATTCCGAAGAA | 18 | 55.56 | 29230 | 29213 | R | -21404.2 | US |
| BA.4.1 | N | US-CDC-N-2 | TTACAAACATTGGCCGCAAA | 20 | 40 | 29164 | 29183 | F | -21115.5 | US |
| BA.4.1 | N | US-CDC-N-2 | GCGCGACATTCCGAAGAA | 18 | 55.56 | 29230 | 29213 | R | -21404.2 | US |
| BA.5.2.1 | N | US-CDC-N-2 | TTACAAACATTGGCCGCAAA | 20 | 40 | 29164 | 29183 | F | -21115.5 | US |
| BA.5.2.1 | N | US-CDC-N-2 | GCGCGACATTCCGAAGAA | 18 | 55.56 | 29230 | 29213 | R | -21404.2 | US |
| BA.5.2.3 | N | US-CDC-N-2 | TTACAAACATTGGCCGCAAA | 20 | 40 | 29164 | 29183 | F | -21115.5 | US |
| BA.5.2.3 | N | US-CDC-N-2 | GCGCGACATTCCGAAGAA | 18 | 55.56 | 29230 | 29213 | R | -21404.2 | US |
| JN.1.8.4 | N | US-CDC-N-2 | TTACAAACATTGGCCGCAAA | 20 | 40 | 29164 | 29183 | F | -21115.5 | US |
| JN.1.8.4 | N | US-CDC-N-2 | GCGCGACATTCCGAAGAA | 18 | 55.56 | 29230 | 29213 | R | -21404.2 | US |
| LV.2 | N | US-CDC-N-2 | TTACAAACATTGGCCGCAAA | 20 | 40 | 29164 | 29183 | F | -21115.5 | US |
| LV.2 | N | US-CDC-N-2 | GCGCGACATTCCGAAGAA | 18 | 55.56 | 29230 | 29213 | R | -21404.2 | US |
| JN.1.54.1 | N | US-CDC-N-2 | TTACAAACATTGGCCGCAAA | 20 | 40 | 29164 | 29183 | F | -21115.5 | US |
| JN.1.54.1 | N | US-CDC-N-2 | GCGCGACATTCCGAAGAA | 18 | 55.56 | 29230 | 29213 | R | -21404.2 | US |
| JN.7 | N | US-CDC-N-2 | TTACAAACATTGGCCGCAAA | 20 | 40 | 29164 | 29183 | F | -21115.5 | US |
| JN.7 | N | US-CDC-N-2 | GCGCGACATTCCGAAGAA | 18 | 55.56 | 29230 | 29213 | R | -21404.2 | US |
| JN.1.30.1 | N | US-CDC-N-2 | TTACAAACATTGGCCGCAAA | 20 | 40 | 29164 | 29183 | F | -21115.5 | US |
| JN.1.30.1 | N | US-CDC-N-2 | GCGCGACATTCCGAAGAA | 18 | 55.56 | 29230 | 29213 | R | -21404.2 | US |
| KP.1.1.4 | N | US-CDC-N-2 | TTACAAACATTGGCCGCAAA | 20 | 40 | 29164 | 29183 | F | -21115.5 | US |
| Lineage (WHO label) | Target Gene | Primer Name | Primer Sequence | Primer Length | Primer GC Content (%) | Start Position | End Position | Primer Direction | ΔG (cal) | Primer first used |